The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Is long-acting HIV treatment as good as taking daily pills? Treatment for people living with HIV (antiretroviral therapy) is ...

A groundbreaking Phase 1 study suggests that once-yearly intramuscular lenacapavir could be a promising option for HIV PrEP.

She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

Both TB treatment and TB preventive therapy involve taking lots of pills, usually for several months. Researchers are working ...